Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00788892 · ClinicalTrials.gov registry record · Phase 2
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT00788892 is a Phase 2 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 126 participants.
The verdict
NCT00788892, a Phase 2 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
The study investigates if CPX-351 will be a) more effective than the standard AML treatment and b) more tolerable than the standard AML treatment regimens. The study compares the investigational product CPX-351 vs the standard treatment for AML in this patients age group.
Interventions
- DRUG Cytarabine
- DRUG Daunorubicin
- DRUG CPX-351
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00788892
The ClinicalTrials.gov registry entry for NCT00788892 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cytarabine is the first listed.
NCT00788892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00788892 about?
NCT00788892 is a clinical study titled "Trial of CPX-351 in Newly Diagnosed Elderly AML Patients". The study investigates if CPX-351 will be a) more effective than the standard AML treatment and b) more tolerable than the standard AML treatment regimens. The study compares the investigational product CPX-351 vs the standard treatment for AML in this patients age group.
What is the current status of trial NCT00788892?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2008-10. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00788892?
The interventions under investigation include: Cytarabine (DRUG), Daunorubicin (DRUG), CPX-351 (DRUG).
Who is sponsoring clinical trial NCT00788892?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.